Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts.
Abstract
Cultured rat lung fibroblasts were used to explore desensitization of guanylate cyclase to nitrovasodilators. The effect of pretreatment with glyceryl trinitrate (GTN) on the concentration-response curves of GTN and sodium nitroprusside (SNP) for cyclic GMP accumulation in intact cells and activation of guanylate cyclase in broken cell preparations was measured. Pretreatment of cells with 1 microM GTN for 3 h decreased cyclic GMP accumulation induced by GTN but had no effect on SNP-induced cyclic GMP accumulation. Pretreatment of cells with 100 microM GTN decreased the efficacy of GTN and SNP for cyclic GMP elevation by 89% and 40%, respectively. In contrast to results obtained with GTN, SNP slightly desensitized cyclic GMP accumulation induced by GTN and SNP. Pretreatment of cells with 100 nM atrial natriuretic peptide resulted in a 44% decrease in cyclic GMP accumulation induced by subsequent exposure to 10 nM atrial natriuretic peptide but had no effect on cyclic GMP elevation induced by nitrovasodilators. In experiments with crude preparations of soluble guanylate cyclase from cells pretreated with 1 mM GTN, activation of the enzyme by GTN and SNP was inhibited almost completely. Tolerance to GTN in intact cells could not be reversed by subsequent incubation with thiols such as cysteine, N-acetylcysteine or glutathione. However, overnight incubation of GTN-tolerant cells in media without added thiols resulted in complete recovery of responsiveness to GTN. Recovery of GTN-induced cyclic GMP accumulation was inhibited in a concentration-dependent manner by cycloheximide, suggesting that reversal of organic nitrate tolerance requires de novo synthesis of gyanylate cyclase.(ABSTRACT TRUNCATED AT 250 WORDS)
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ADMA was recognized as an important marker for cardiovascular disease progression soon after its discovery in cells and tissue.
“Soon after its discovery in cells and tissue, ADMA was recognized as an important marker for cardiovascular disease progression (656, 829, 961, 1011, 1053, 1068).”
From Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation (2019) · cites this paper as [829]
Cited by
Sorted by citations
Nitric oxide donors: chemical activities and biological applications
Wang, P. G., Xian, M., Tang, X., Wu, X., Wen, Z., Cai, T., & Janczuk, A. J. (2002) · Chemical Reviews · doi:10.1021/cr000040l · Cited by 1,337 · see citing works
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541 · see citing works
Structure and Regulation of Soluble Guanylate Cyclase
Derbyshire, E. R., & Marletta, M. A. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-050410-100030 · Cited by 466 · see citing works
Effects of Cyclic GMP on Smooth Muscle Relaxation
Warner, T. D., Mitchell, J. A., Sheng, H., & Murad, F. (1994) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60054-x · Cited by 117 · see citing works
Self-citationGhosh, A., & Stuehr, D. J. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6690 · Cited by 19 · see citing works
- Authors
- Schröder, H., Leitman, D. C., Bennett, B. M., Waldman, S. A., & Murad, F.
- Affiliations
- Stanford Medicine (US)
- VA Palo Alto Health Care System (US)
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1988-05
- Volume
- 245
- Issue
- 2
- Pages
- 413-418
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1923972005
- Cited by
- 85
- References
- 0
- Citations by year
- 2020: 1 · 2019: 1 · 2018: 1 · 2016: 3 · 2014: 2 · 2013: 1 · 2012: 4
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed
- Funders
- National Institutes of Health (5r01am030787-05)
- National Heart, Lung, and Blood Institute (HL-28474)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
- Keywords
- nitroglycerin, nitrovasodilators, sodium nitroprusside, lung fibroblasts, atrial natriuretic peptide, thiols, cycloheximide, enzyme recovery, soluble guanylate cyclase
- MeSH terms
- Animals, Cells, Cultured, Cycloheximide, Enzyme Activation, Fibroblasts, Glutathione, Nitroglycerin, Guanylate Cyclase, Kinetics, Lung, Nitroprusside, 1-Methyl-3-isobutylxanthine, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review